Sensorion is participating in the ASGCT annual conference

Sensorion, a biotechnology company specializing in the treatment of hearing loss disorders, announces its participation in the 29th annual conference of the American Society for Gene and Cell Therapy (ASGCT). This event will take place in Boston from May 11 to 15, 2026. Sensorion will present two posters during the conference.

Laurent Desire, head of preclinical development, will present on the safety and efficacy of SENS-601, a gene therapy for non-syndromic type 1A deafness. Marina Dos Santos, DSP manager, will present the development of a recombinant AAV serotype. The presentations will take place on May 12 at the Thomas M. Menino Convention & Exhibition Center.